• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

cancer drugs

Eraser and chalk on a chalkboard
Biotech

CNS Pharma wipes glioblastoma pipeline clean in strategic pivot

The biotech is seeking partners to take its old assets off its hands while shopping for promising new prospects in neurology and oncology.
Darren Incorvaia Mar 11, 2026 10:30am
pipeline valve pipe flow water tap

Ono’s Deciphera drops early-stage solid tumor drug

Mar 3, 2026 7:47pm
A wolf that looks sad

Werewolf weighs sale or merger as cash reserves whimper

Feb 24, 2026 5:23pm
Glowing puzzle piece fitting into puzzle

Gilead pens $1.5B Genhouse deal for synthetic lethal therapy

Feb 16, 2026 2:00pm
Surge

Langer-backed biotech looks to end cancer recurrence

Feb 12, 2026 8:00am
money funding financing bank

Eikon sets $274M goal for upcoming stock market debut

Jan 28, 2026 2:00pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings